Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned an average recommendation of “Hold” from the five analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $5.50.

A number of equities research analysts have recently issued reports on MRVI shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday. Finally, Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a report on Friday, May 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada increased its holdings in shares of Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares during the last quarter. Barclays PLC boosted its position in Maravai LifeSciences by 3.0% during the fourth quarter. Barclays PLC now owns 172,281 shares of the company’s stock worth $560,000 after purchasing an additional 5,057 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Maravai LifeSciences by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after purchasing an additional 5,160 shares during the last quarter. Epacria Capital Partners LLC increased its holdings in shares of Maravai LifeSciences by 6.8% in the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock valued at $287,000 after purchasing an additional 6,384 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Maravai LifeSciences by 2.7% in the first quarter. Bank of New York Mellon Corp now owns 343,643 shares of the company’s stock valued at $973,000 after purchasing an additional 8,955 shares during the period. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Stock Down 0.2%

Maravai LifeSciences stock traded down $0.01 during mid-day trading on Wednesday, reaching $4.82. The company’s stock had a trading volume of 443,296 shares, compared to its average volume of 1,793,087. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.96 and a current ratio of 5.91. Maravai LifeSciences has a 12 month low of $1.99 and a 12 month high of $4.99. The business’s 50 day simple moving average is $3.69 and its 200 day simple moving average is $3.55. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -6.79 and a beta of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. As a group, research analysts anticipate that Maravai LifeSciences will post -0.2 earnings per share for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.